Don't miss

Replay


LATEST SHOWS

ENCORE!

Opera singers Thomas Hampson & Luca Pisaroni return to Paris

Read more

FOCUS

Hunger has forced many Nigerian refugees in northern Cameroon to return to dangerous Boko Haram territory.

Read more

BUSINESS DAILY

US investigating China's intellectual property policy

Read more

IN THE PAPERS

Bonnie Tyler to sing 'Total Eclipse of the Heart' during total solar eclipse

Read more

IN THE PAPERS

Fighting back: How can Europe protect citizens from 'soft target' terrorism?

Read more

EYE ON AFRICA

Kenya’s opposition files a petition against presidential vote

Read more

MEDIAWATCH

'Siempre vida Barcelona'

Read more

THE DEBATE

Spain attacks - Can Europe prepare for vehicle-ramming terror attacks?

Read more

EYE ON AFRICA

Measures in place to prevent Grace Mugabe leaving South Africa

Read more

Cancer drug may help avert transplant rejection

Latest update : 2008-12-27

The bortezomib, a cancer treatment drug, has been tested successfully on several patients whose bodies had been rejecting transplanted organs, an American study found, concluding to "significant implications for transplantation."

AFP - A drug used to treat cancer has proven effective at stopping the body from rejecting a transplanted organ when other treatments failed, a study published Saturday found.
  
US researchers administered the drug, bortezomib, to six patients whose immune systems were attacking transplanted kidneys and who did not respond to traditional anti-rejection treatments.
  
In each case, the drug promptly reversed the rejection, improved organ function, provided prolonged reductions in antibody levels and suppressed recurrent rejection for at least five months.
  
"This has significant implications for transplantation and auto immune disease," said study co-author Steve Woodle, chief of transplant surgery at the University of Cincinnati in Ohio.
  
Woodle's team is currently conducting four clinical trials to expand upon these preliminary findings.
  
The drug's side effects proved to be both predictable and manageable and toxicity levels were much less than those associated with other anti-cancer agents, the study found.
  
"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," said study co-author Jason Everly, an oncology pharmacist at the University of Cincinnati.
  
"We hope it will be a viable therapeutic treatment option in this patient group."
  
Previous studies had found that B-cells play a large role in organ rejection by making immune proteins that attack transplants.
  
The drug targets these antibody-producing plasma cells and had been shown to suppress transplant rejection in the laboratory before Woodle and his team tested it on patients.
  
The study was published in the journal Transplantation.

Date created : 2008-12-27

COMMENT(S)